Teva Pharmaceutical Industries stock
TEVANYSETeva Pharmaceutical Industries Limited, HealthcareISIN IL0006290147
54Score 54 out of 100, Neutral
Price and trend
84 / 100
Price history
+69% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 25% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 73).
The price is at its 52-week high. Largest decline in 20 years: 91% (July 2015 to August 2019).
Chart figures for advanced users
- SMA 50$40.03
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$35.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)73
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$24.21
- The lowest closing price of the last twelve months.
- Resistance$43.65
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Teva Pharmaceutical Industries Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (Israel) and, with a market value of $50.93B, is number 4 of 77 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $16.77B (down 2.8%) and adjusted earnings per share of $2.05 (down 29.7%).
- MEQIRI Score 54 out of 100 (Neutral): rank 346 of 702 in Healthcare, median 53.
Show more
- The P/E is 102.1 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 23.2).
- Our model puts fair value at $23.60, with the price 85% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 244% of earnings over the last 12 months.Fundamentals 63
- Analysts expect strong earnings growthUp 23.4% a year through 2028 (estimates from 10 analysts).
Weaknesses
- Richly valuedP/E 102.1, Drug Manufacturers (Specialty & Generic) median 18.9, own median 23.2.Valuation 18
- Above fair valuePrice 85% above the fair value of $23.60.Valuation 18
- High debtDebt 2.13 times equity (latest quarter), Drug Manufacturers (Specialty & Generic) median 0.49.Stability 36
Its standout strengths are momentum and technical analysis, while stability and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price up very strongly over the past year
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $16.86 and expensive above $39.33 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $39.11 (cash-flow model) and $8.09 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.8%. At 10.8% the fair value would be $20.35, at 8.8% it would be $28.21.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2.7% on the twelve months before. Revenue has grown solidly since 2006, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 52%, operating 12%, net 8%. Last 12 months: net 3%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 27 Jan 2027in 75 days
- Last reported
- 3 Nov 2026EPS reported $0.86 (expected $0.72)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.05+2.7%
- Revenue
- $16.77B+2.5%
- Earnings per share
- $3.11+2.6%
- Revenue
- $17.36B+2.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +11.8%2026 revenue guidance midpoint raised by $75 million to $16.5 billion to $16.8 billion, with other targets reaffirmed.
“Our growth is really accelerating with revenue moving from $4.9 billion in 2022 to an expected $16.5 billion to $16.8 billion this year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 14 insiders sold, $46.17M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sabag MarkSale
12 Nov 2026, See "Remarks"
- Shares
- 44,710
- Price
- $44.14
- Value
- $1.97M
- Daniell RichardSale
11 Nov 2026, EVP, Europe Commercial
- Shares
- 20,003
- Price
- $42.80
- Value
- $856,154
- Francis Richard DSale
10 Nov 2026, President and CEO
- Shares
- 250,000
- Price
- $42.24
- Value
- $10.56M
Show 18 more
- Daniell RichardSale
9 Nov 2026, EVP, Europe Commercial
- Shares
- 25,000
- Price
- $42.91
- Value
- $1.07M
- Weiss AmirSale
9 Nov 2026, Chief Accounting Officer
- Shares
- 17,289
- Price
- $43.04
- Value
- $744,049
- Sabag MarkSale
5 Nov 2026, See "Remarks"
- Shares
- 46,000
- Price
- $41.93
- Value
- $1.93M
- Bergwerk DovSale
4 Nov 2026, Interim Cheif Legal Officer
- Shares
- 8,755
- Price
- $41.72
- Value
- $365,259
- Savage BrianSale
18 Sept 2026, Interim Chief Legal Officer
- Shares
- 7,342
- Price
- $38.85
- Value
- $285,215
- Mignone RobertoSale
18 Sept 2026, Board
- Shares
- 367,600
- Price
- $39.06
- Value
- $14.36M
- Weiss AmirSale
21 Aug 2026, Chief Accounting Officer
- Shares
- 9,445
- Price
- $37.62
- Value
- $355,301
- Satchi-Fainaro RonitSale
21 Aug 2026, Board
- Shares
- 415
- Price
- $37.25
- Value
- $15,459
- Lippman EvanSale
17 Aug 2026, EVP, Business Development
- Shares
- 18,600
- Price
- $36.57
- Value
- $680,291
- Zaks Tal ZviSale
5 Aug 2026, Board
- Shares
- 17
- Price
- $34.87
- Value
- $593
- Jover PlacidSale
3 Aug 2026, See "Remarks"
- Shares
- 12,827
- Price
- $34.88
- Value
- $447,351
- Hughes Eric ASale
3 Aug 2026, See "Remarks"
- Shares
- 25,578
- Price
- $34.88
- Value
- $892,051
- Shields MatthewSale
18 Jun 2026, EVP, Global Operations
- Shares
- 9,989
- Price
- $32.19
- Value
- $321,547
- Kalif Eliyahu SharonSale
11 Jun 2026, EVP, Chief Financial Officer
- Shares
- 106,563
- Price
- $34.10
- Value
- $3.63M
- Francis Richard DSale
5 Jun 2026, President and CEO
- Shares
- 6,153
- Price
- $34.35
- Value
- $211,356
- Shields MatthewSale
3 Jun 2026, EVP, Global Operations
- Shares
- 16,195
- Price
- $32.87
- Value
- $532,330
- Lippman EvanSale
14 May 2026, EVP, Business Development
- Shares
- 41,658
- Price
- $35.58
- Value
- $1.48M
- Kalif Eliyahu SharonSale
14 May 2026, EVP, Chief Financial Officer
- Shares
- 153,251
- Price
- $35.61
- Value
- $5.46M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Teva Pharmaceutical Industries
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 54
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Merck KGaAMRK.DE $71.38B67
- Takeda PharmaceuticalTAK $68.52B57
- Galderma GroupGALD.SW $54.41B64
- Sun Pharmaceutical IndustriesSUNPHARMA.NS $48.07B72
- Jiangsu Hengrui Medicine600276.SS $45.85B69
- Sandoz GroupSDZ.SW $45.13B66
- Jiangsu Hengrui Pharmaceuticals1276.HK $42.06B67
- HaleonHLN $39.95B61
ETFs that hold Teva Pharmaceutical Industries
Held by 19 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI World Momentum Factor Advanced UCITS ETFCBUH | 0.33% | 0.25% | €267.4M |
| iShares Edge MSCI World Value Factor UCITS ETFIS3S | 0.26% | 0.25% | €6.33B |
| iShares MSCI World ex-USA UCITS ETF USD (Acc)IXUA | 0.22% | 0.15% | €3.43B |
Show 5 more
| iShares Edge MSCI World Momentum Factor UCITS ETF USD (Acc)IS3R | 0.21% | 0.25% | €5.09B |
| iShares World Equity High Income Active UCITS ETF USDWINC | 0.19% | 0.35% | €955.74M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.13% | 0.18% | €839.61M |
| iShares MSCI World UCITS ETF USD (Dist)IQQW | 0.06% | 0.50% | €8.56B |
| iShares MSCI World Screened UCITS ETFSNAW | 0.06% | 0.20% | €5.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.